PMS-SALBUTAMOL SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SALBUTAMOL (SALBUTAMOL SULFATE)

可用日期:

PHARMASCIENCE INC

ATC代码:

R03AC02

INN（国际名称）:

SALBUTAMOL

剂量:

0.5MG

药物剂型:

SOLUTION

组成:

SALBUTAMOL (SALBUTAMOL SULFATE) 0.5MG

给药途径:

INHALATION

每包单位数:

20 X 2.5ML

处方类型:

Prescription

治疗领域:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

產品總結:

Active ingredient group (AIG) number: 0108887009; AHFS:

授权状态:

APPROVED

授权日期:

2010-05-04

产品特点

PRODUCT MONOGRAPH
PR
PMS-SALBUTAMOL
Salbutamol Sulphate Inhalation Solution, BP
0.05%; 0.1%; 0.2%
0.5 mg/mL; 1 mg/mL; 2 mg/mL
BRONCHODILATOR
Beta
2
-adrenergic stimulant
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
Date of Revision:
August 10, 2018
www.pharmascience.com
Submission Control No: 217525
_ _
_pms-SALBUTAMOL Product Monograph Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
....................................................................................................
8
DOSAGE AND ADMINISTRATION
................................................................................
9
OVERDOSAGE
................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 11
STORAGE AND STABILITY
.........................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 13
PART II: SCIENTIFIC INFORMATION
...............................................................................
14
PHARMACEUTICAL INFORMATION
.........................................................................
14
CLINICAL TRIALS
...........................................................................................